Nama's AI scorecard currently rates BeOne Medicines Buy (7.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is ONC's P/E ratio?

BeOne Medicines trades at a trailing price-to-earnings ratio of 51.7.

When does ONC report earnings?

BeOne Medicines's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $2.38.

What is the ONC price target?

The median analyst price target from 27 analysts is $439.41, with a range of $385.00 – $528.00.

Is ONC Shariah compliant?

Nama's AAOIFI-style screen reads BeOne Medicines as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

BeOne Medicines (ONC)

Healthcare · Biotechnology · NASDAQ

BeOne Medicines (ONC) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $46.30B, a trailing price-to-earnings ratio of 51.7 and a free-cash-flow yield of 1.9%. Over the most recent reported fiscal year, revenue grew 40.2%. Nama's AI scorecard rates it Buy, 7.3 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Buy · 7.3/10

Clearly positive, short of the top band. As of Nov 7, 2026.

Momentum

Middle · +9.5% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-0.9%

How far the last close sits under the highest price of the past five years.

Market cap	$46.30B
Trailing P/E	51.7
Price / book	115.6
Price / sales	7.5
FCF yield	1.9%
Dividend yield	—
Gross margin	88.9%
Operating margin	15.1%
Net margin	10.7%
Revenue growth (YoY)	+40.2%
Revenue growth (3-yr annual)	+55.7%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	0.6
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

ONC earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate $2.38). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 5, 2026	$3.28	$1.88	+74.5%	$1.89B
Q2 2026	Aug 5, 2026	$2.05	$1.63	+25.8%	$1.71B
Q1 2026	May 6, 2026	$1.96	$0.81	+142.0%	$1.51B
Q4 2025	Feb 26, 2026	$0.58	$1.30	-55.4%	$1.50B

ONC analyst price target

Median target $439.41 from 27 analysts, ranging $385.00 – $528.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9
ROIV	Roivant Sciences	$28.08B	—

Explore live ONC data on Nama Insights →

ONC FAQ

Is ONC a buy?: Nama's AI scorecard currently rates BeOne Medicines Buy (7.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is ONC's P/E ratio?: BeOne Medicines trades at a trailing price-to-earnings ratio of 51.7.
When does ONC report earnings?: BeOne Medicines's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $2.38.
What is the ONC price target?: The median analyst price target from 27 analysts is $439.41, with a range of $385.00 – $528.00.
Is ONC Shariah compliant?: Nama's AAOIFI-style screen reads BeOne Medicines as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.